Bridget Oppong named deputy director of Ohio State’s Center for Cancer Health Equity

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

The web page for the FDA Office of Minority Health and Health Equity is no more. The pages for the NCI Diversity Training and Biomedical Workforce Development Branch and Disparities Research Branch are kaput as well.

February 07, 2025

Vol.51 No.05

By Jacquelyn Cobb and Katie Goldberg

Black History Month In the Archives

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath

When Marsha B. Henderson, former FDA Associate Commissioner of Women’s Health (1998-2019), sat down for an oral history interview upon her retirement from the agency, she could not have foreseen becoming party to a government digital purge 7 years later. Over the past week, the Trump administration has been busy at work deleting government webpages...

COA proposes health care reform blueprint

The Community Oncology Alliance released the COA Prescription for Health Care Reform, a blueprint that diagnoses the fundamental challenges facing the U.S. healthcare system, outlines the consequences for patients across America, and presents “actionable solutions .”

February 07, 2025

Vol.51 No.05

Clinical Roundup

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA approves Enhertu as first HER2-directed therapy for breast cancer

FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by the FDA approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

January 31, 2025

Vol.51 No.04

Conversation with The Cancer Letter Real-world Evidence

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.

January 24, 2025

Vol.51 No.03

By Claire Marie Porter

Bridget Oppong named deputy director of Ohio State’s Center for Cancer Health Equity

YOU MAY BE INTERESTED IN

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath

COA proposes health care reform blueprint

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

FDA approves Enhertu as first HER2-directed therapy for breast cancer

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

Renew today!

Subscriber content

Never miss an issue!

Login

Bridget Oppong named deputy director of Ohio State’s Center for Cancer Health Equity

YOU MAY BE INTERESTED IN

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and genderMedical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”Preserving an oral history by the former FDA associate commissioner of women’s heath

COA proposes health care reform blueprint

Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds

FDA approves Enhertu as first HER2-directed therapy for breast cancer

RWD company documents baseline trends in women’s cancers before Trump’s policy changes

Never miss an issue!

Login

“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions”

Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”
Preserving an oral history by the former FDA associate commissioner of women’s heath